Examine the Japanese Pharmaceuticals and Healthcare Industry with ...

Tag : Pharmaceuticals
Research and Markets(http://www.researchandmarkets.com/research/6d2dfc/japan_pharmaceutic)has announced the addition of the "Japan Pharmaceuticals andHealthcare Report Q3 2008" report to their offering.

BMI's Japan Pharmaceuticals and Healthcare Report providesindependent forecasts and competitive intelligence on Japan'spharmaceuticals and healthcare industry.

Japan has the second largest pharmaceutical market in the world,currently valued at approximately US$76bn. Using BMI's proprietaryforecast model, sales of prescription drugs and over-the-counter(OTC) medicines are expected to be US$85.5bn by 2012. The market ischaracterised by the 'drug lag', a preference for brandedmedication, dominance by local firms and an emerging generic drugsector.

Japan's US$5.03bn over-the-counter (OTC) market is on the brink ofa paradigm shift. The Ministry of Health, Labour and Welfare (MHLW)plans to allow convenience stores, supermarkets and other retailoutlets to sell consumer healthcare products - such cough and coldremedies and analgesics - in April 2009. If this legislation ispassed, as BMI expects, we will upgrade the sector forecastsignificantly.

Pricing and reimbursement in Japan is highly complex and opaque,which results in drugs reaching the market long after regulatorysubmissions are made. Consequentially, the system has receivedcriticism from both pharmaceutical companies and patient groups,which have to wait for medical breakthroughs. In an effort todiversify and increase its presence in emerging markets, Japanesedrugmaker Daiichi Sankyo purchased a controlling stake in Indiangenerics firm Ranbaxy Laboratories during Q308.

Daiichi is not the first Japanese drugmaker to adapt to theincreasingly tough operating environment. In April 2008, TakedaPharmaceuticals agreed to pay US$8.8bn for US drugmaker MillenniumPharmaceuticals. The transaction gave the Japanese company accessto the blood cancer drug Velcade (bortezomib), which is forecast toproduce US$345mn in sales during 2008 - a 25% increase on theprevious year. This deal was followed by Eisai's purchase of cancerspecialist MGI Pharma for US$3.9bn in Q407.

Certain industry stakeholders criticised the plan proposed by theFederation of Pharmaceutical Manufacturers Association of Japan(FPMAJ) in July 2008 to update the prescription drug pricingprocedures. Not unsurprisingly, the drugmakers are seeking tocharge higher prices for longer periods as well as secure morepremiums for improving clinical outcomes. In light of the globaltrend for cost containment in developed states, BMI does not expectthe changes to be implemented.

Key Topics Covered:

Executive Summary

Japan Pharmaceuticals And Healthcare Industry SWOT

Japan Political SWOT

Japan Economic SWOT

Pharmaceutical Business Environment Ratings

Limits Of Potential Returns

Risks To Realisation Of Returns

Japan - Market Summary

Regulatory Regime

Recent Regulatory Developments

Medical Device Regulations

Intellectual Property Developments

Pricing And Reimbursement System

Recent Pricing And Reimbursement Developments

Other Regulatory Issues

Industry Trends And Developments

Epidemiology

Healthcare Sector

Healthcare Sector Finance Issues

Healthcare Reforms

International Collaboration

International Reaction

Domestic Company Activity

Foreign Generic Sector

Multinational Sector Developments

Research And Development

Industry Forecast Scenario

Overall Market Forecast

Key Growth Factors - Industry

Macroeconomic Forecast Scenario

Prescription Market Forecast

OTC Market Forecast

Generics Market Forecast

Generics Market Forecast

Patented Medicines Market Forecast

Export/Import Forecasts

Other Healthcare Data And Forecasts

Key Risks To BMI's Forecast Scenario

Competitive Landscape

Company Profiles

Leading Foreign Manufacturers

Pfizer

Sanofi-Aventis

Merck & Co (Banyu)

Novartis

GlaxoSmithKline (GSK)

AstraZeneca

Indigenous Manufacturers

Takeda

Astellas

Eisai

Daiichi-Sankyo

Sawai Pharmaceutical

BMI Forecast Modelling

How We Generate Our Pharmaceutical Industry Forecasts

Pharmaceutical Industry

Pharmaceutical Business Environment Ratings Methodology

Ratings Overview

Weighting

Sources

Companies Mentioned:

- Pfizer

- Sanofi-Aventis

- Merck & Co (Banyu)

- Novartis

- GlaxoSmithKline (GSK)

- AstraZeneca

- Takeda

- Astellas

- Eisai

- Daiichi-Sankyo

- Sawai Pharmaceutical

For more information visithttp://www.researchandmarkets.com/research/6d2dfc/japan_pharmaceutic